[The protective effect and mechanism of anti-IGFBPrP1 antibody for hepatic fibrosis induced thioacetamide].
Xu
Jun-jun
JJ
Shanxi Medical University, the First Hospital, Institute of Hepatopathy, the Key Laboratory of Cell Physiology, Provincial Department of Ministry of Education, Taiyuan, China.
Liu
Li-xin
LX
Zhang
Qian-qian
QQ
Zhang
Hai-yan
HY
D000410:Alanine Transaminase / Q000097:blood; D000818:Animals; D000906:Antibodies / Q000494:pharmacology*; D017209:Apoptosis; D024042:Collagen Type I / Q000096:biosynthesis; D004268:DNA-Binding Proteins / Q000378:metabolism; D004195:Disease Models, Animal; D018970:Insulin-Like Growth Factor Binding Protein 1 / Q000276:immunology*; D007770:L-Lactate Dehydrogenase / Q000097:blood; D008099:Liver / Q000187:drug effects / Q000378:metabolism / Q000473:pathology; D008106:Liver Cirrhosis, Experimental / Q000188:drug therapy* / Q000276:immunology* / Q000378:metabolism; D008297:Male; D051379:Mice; D020011:Protective Agents / Q000494:pharmacology*; D013853:Thioacetamide; D016212:Transforming Growth Factor beta / Q000378:metabolism
D000906:Antibodies; D024042:Collagen Type I; D004268:DNA-Binding Proteins; D018970:Insulin-Like Growth Factor Binding Protein 1; D020011:Protective Agents; D016212:Transforming Growth Factor beta; D013853:Thioacetamide; D007770:L-Lactate Dehydrogenase; D000410:Alanine Transaminase